MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
March 02, 2020
- PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR
- AAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation
LONDON and NEW YORK,
PRIME designation was granted based on clinical data from
“XLRP is a severe disease which causes rapid progression to blindness and total loss of vision in most patients by the fourth decade,” said
To be eligible for PRIME, medicinal products must be of major public health interest and target conditions where there is an unmet medical need. To determine PRIME eligibility, the EMA considers whether the available data suggest that the product may potentially offer a major therapeutic advantage to patients in a given indication through a clinically meaningful improvement, such as having an impact on the prevention, onset and duration of the condition, or improving the morbidity or mortality of the disease. To be accepted for PRIME, early clinical data must demonstrate the medicine’s potential to benefit patients with unmet medical needs. Features of PRIME designation include guidance and interaction with the EMA on the drug development plan, including early interactions to discuss the regulatory pathway and potential ways to generate data packages designed to address EMA Marketing Authorization Application (MAA) requirements.
ATMP status is granted to medicines that are based on genes, tissues or cells and can offer groundbreaking new opportunities for the treatment of disease. All advanced therapy medicines are authorized centrally via the EMA and may benefit from a single evaluation and authorization procedure.
For more information about the ongoing clinical trial, please visit https://clinicaltrials.gov/ct2/show/NCT03252847.
AAV-RPGR is an investigational gene therapy for the treatment of patients with XLRP caused by mutations in the eye specific form of the RPGR gene (RPGR ORF15). AAV-RPGR is designed to deliver functional copies of the RPGR gene to the subretinal space in order to improve and preserve visual function.
About X-Linked Retinitis Pigmentosa (XLRP)
XLRP is the most severe form of retinitis pigmentosa (RP), a group of inherited retinal diseases characterized by progressive retinal degeneration and vision loss. In XLRP, both rods and cones function poorly, leading to degeneration of the retina and total blindness. The most frequent mutation causing XLRP is in the RPGR gene accounting for more than 70% of cases of XLRP and up to 20% of all cases of RP. There are currently no approved treatments for XLRP.
For more information, please visit www.meiragtx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our ability to work with the EMA to accelerate the clinical development and potential approval of AAV-RPGR, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, acquire additional capital, identify additional and develop existing product candidates, successfully execute strategic priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended